Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Mol Biol ; 434(2): 167349, 2022 01 30.
Artículo en Inglés | MEDLINE | ID: mdl-34774565

RESUMEN

Imatinib is an ATP-competitive inhibitor of Bcr-Abl kinase and the first drug approved for chronic myelogenous leukemia (CML) treatment. Here we show that imatinib binds to a secondary, allosteric site located in the myristoyl pocket of Abl to function as an activator of the kinase activity. Abl transitions between an assembled, inhibited state and an extended, activated state. The equilibrium is regulated by the conformation of the αΙ helix, which is located nearby the allosteric pocket. Imatinib binding to the allosteric pocket elicits an αΙ helix conformation that is not compatible with the assembled state, thereby promoting the extended state and stimulating the kinase activity. Although in wild-type Abl the catalytic pocket has a much higher affinity for imatinib than the allosteric pocket does, the two binding affinities are comparable in Abl variants carrying imatinib-resistant mutations in the catalytic site. A previously isolated imatinib-resistant mutation in patients appears to be mediating its function by increasing the affinity of imatinib for the allosteric pocket, providing a hitherto unknown mechanism of drug resistance. Our results highlight the benefit of combining imatinib with allosteric inhibitors to maximize their inhibitory effect on Bcr-Abl.


Asunto(s)
Sitio Alostérico , Mesilato de Imatinib/química , Mesilato de Imatinib/farmacología , Regulación Alostérica/efectos de los fármacos , Sitio Alostérico/genética , Antineoplásicos/farmacología , Dominio Catalítico , Resistencia a Antineoplásicos/efectos de los fármacos , Humanos , Mesilato de Imatinib/uso terapéutico , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Modelos Moleculares , Mutación , Inhibidores de Proteínas Quinasas/farmacología
2.
Structure ; 30(1): 69-79.e2, 2022 01 06.
Artículo en Inglés | MEDLINE | ID: mdl-34914892

RESUMEN

Methyl-TROSY spectroscopy has extended the reach of solution-state NMR to supra-molecular machineries over 100 kDa in size. Methyl groups are ideal probes for studying structure, dynamics, and protein-protein interactions in quasi-physiological conditions with atomic resolution. Successful implementation of the methodology requires accurate methyl chemical shift assignment, and the task still poses a significant challenge in the field. In this work, we outline the current state of technology for methyl labeling, data collection, data analysis, and nuclear Overhauser effect (NOE)-based automated methyl assignment approaches. We present MAGIC-Act and MAGIC-View, two Python extensions developed as part of the popular NMRFAM-Sparky package, and MAGIC-Net a standalone structure-based network analysis program. MAGIC-Act conducts statistically driven amino acid typing, Leu/Val pairing guided by 3D HMBC-HMQC, and NOESY cross-peak symmetry checking. MAGIC-Net provides model-based NOE statistics to aid in selection of a methyl labeling scheme. The programs provide a versatile, semi-automated framework for rapid methyl assignment.


Asunto(s)
Proteínas/química , Proteínas/metabolismo , Algoritmos , Aminoácidos , Humanos , Metilación , Modelos Moleculares , Resonancia Magnética Nuclear Biomolecular , Unión Proteica , Proteínas/genética
3.
Science ; 370(6513)2020 10 09.
Artículo en Inglés | MEDLINE | ID: mdl-33004676

RESUMEN

Protein kinases intrinsically sample a number of conformational states with distinct catalytic and binding activities. We used nuclear magnetic resonance spectroscopy to describe in atomic-level detail how Abl kinase interconverts between an active and two discrete inactive structures. Extensive differences in key structural elements between the conformational states give rise to multiple intrinsic regulatory mechanisms. The findings explain how oncogenic mutants can counteract inhibitory mechanisms to constitutively activate the kinase. Energetic dissection revealed the contributions of the activation loop, the Asp-Phe-Gly (DFG) motif, the regulatory spine, and the gatekeeper residue to kinase regulation. Characterization of the transient conformation to which the drug imatinib binds enabled the elucidation of drug-resistance mechanisms. Structural insight into inactive states highlights how they can be leveraged for the design of selective inhibitors.


Asunto(s)
Genes abl , Mesilato de Imatinib/química , Inhibidores de Proteínas Quinasas/química , Proteínas Tirosina Quinasas/química , Biocatálisis , Humanos , Mutación , Resonancia Magnética Nuclear Biomolecular , Oligopéptidos/química , Oligopéptidos/genética , Dominios Proteicos , Estructura Secundaria de Proteína , Proteínas Tirosina Quinasas/genética
4.
Mol Cancer Res ; 18(8): 1189-1201, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32321766

RESUMEN

The Crk adaptor protein, a critical modifier of multiple signaling pathways, is overexpressed in many cancers where it contributes to tumor progression and metastasis. Recently, we have shown that Crk interacts with the peptidyl prolyl cis-trans isomerase, Cyclophilin A (CypA; PP1A) via a G219P220Y221 (GPY) motif in the carboxyl-terminal linker region of Crk, thereby delaying pY221 phosphorylation and preventing downregulation of Crk signaling. Here, we investigate the physiologic significance of the CypA/Crk interaction and query whether CypA inhibition affects Crk signaling in vitro and in vivo. We show that CypA, when induced under conditions of hypoxia, regulates Crk pY221 phosphorylation and signaling in cancer cell lines. Using nuclear magnetic resonance spectroscopy, we show that CypA binds to the Crk GPY motif via the catalytic PPII domain of CypA, and small-molecule nonimmunosuppressive inhibitors of CypA (Debio-025) disrupt the CypA-CrkII interaction and restores phosphorylation of Crk Y221. In cultured cell lines, Debio-025 suppresses cell migration, and when administered in vivo in an orthotopic model of triple-negative breast cancer, Debio-025 showed antitumor efficacy either alone or in combination with anti-PD-1 mAb, reducing both tumor volume and metastatic lung dispersion. Furthermore, when analyzed by NanoString immune profiling, treatment of Debio-025 with anti-PD-1 mAb increased both T-cell signaling and innate immune signaling in tumor microenvironment. IMPLICATIONS: These data suggest that pharmacologic inhibition of CypA may provide a promising and unanticipated consequence in cancer biology, in part by targeting the CypA/CrkII axis that regulates cell migration, tumor metastasis, and host antitumor immune evasion.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Ciclosporina/administración & dosificación , Inhibidores de Puntos de Control Inmunológico/administración & dosificación , Isomerasa de Peptidilprolil/metabolismo , Proteínas Proto-Oncogénicas c-crk/metabolismo , Animales , Antineoplásicos Inmunológicos/administración & dosificación , Antineoplásicos Inmunológicos/farmacología , Neoplasias de la Mama/metabolismo , Hipoxia de la Célula , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Ciclosporina/farmacología , Sinergismo Farmacológico , Femenino , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Ratones , Modelos Moleculares , Metástasis de la Neoplasia , Isomerasa de Peptidilprolil/química , Fosforilación/efectos de los fármacos , Unión Proteica/efectos de los fármacos , Dominios Proteicos , Proteínas Proto-Oncogénicas c-crk/química , Análisis de Secuencia de ARN , Microambiente Tumoral/efectos de los fármacos
5.
J Biomol NMR ; 69(4): 215-227, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29098507

RESUMEN

Selective methyl labeling is an extremely powerful approach to study the structure, dynamics and function of biomolecules by NMR. Despite spectacular progress in the field, such studies remain rather limited in number. One of the main obstacles remains the assignment of the methyl resonances, which is labor intensive and error prone. Typically, NOESY crosspeak patterns are manually correlated to the available crystal structure or an in silico template model of the protein. Here, we propose methyl assignment by graphing inference construct, an exhaustive search algorithm with no peak network definition requirement. In order to overcome the combinatorial problem, the exhaustive search is performed locally, i.e. for a small number of methyls connected through-space according to experimental 3D methyl NOESY data. The local network approach drastically reduces the search space. Only the best local assignments are combined to provide the final output. Assignments that match the data with comparable scores are made available to the user for cross-validation by additional experiments such as methyl-amide NOEs. Several NMR datasets for proteins in the 25-50 kDa range were used during development and for performance evaluation against the manually assigned data. We show that the algorithm is robust, reliable and greatly speeds up the methyl assignment task.


Asunto(s)
Algoritmos , Resonancia Magnética Nuclear Biomolecular/métodos , Proteínas/química , Conformación Proteica
6.
J Biomol NMR ; 69(4): 237-243, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29164453

RESUMEN

In multidimensional solution NMR experiments, π pulses are used extensively for inversion and refocusing operations on 1H, 13C and 15N nuclei. Pulse miscalibration, off-resonance effects, and J-coupling evolution during π pulse execution result in severe signal losses that are exacerbated at high magnetic fields. Here, we report the implementation of a triply-compensated π pulse (G5) optimized for both inversion and refocusing in widely used 2- and 3-dimensional experiments. By replacing most of the hard π pulses, adiabatic or composite pulses on the 1H, 13C and 15N channels with G5 pulses, we obtained signal enhancements ranging from 80 to 240%. We anticipate that triply-compensated pulses will be crucial for improving the performance of multidimensional and multinuclear pulse sequences at ultra-high fields.


Asunto(s)
Resonancia Magnética Nuclear Biomolecular/métodos
7.
Nat Struct Mol Biol ; 24(11): 893-901, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28945248

RESUMEN

The activity of protein kinases is often regulated in an intramolecular fashion by signaling domains, which feature several phosphorylation or protein-docking sites. How kinases integrate such distinct binding and signaling events to regulate their activities is unclear, especially in quantitative terms. We used NMR spectroscopy to show how structural elements within the Abl regulatory module (RM) synergistically generate a multilayered allosteric mechanism that enables Abl kinase to function as a finely tuned switch. We dissected the structure and energetics of the regulatory mechanism to precisely measure the effects of various activating or inhibiting stimuli on Abl kinase activity. The data provide a mechanistic basis explaining genetic observations and reveal a previously unknown activator region within Abl. Our findings show that drug-resistance mutations in the Abl RM exert their allosteric effect by promoting the activated state of Abl and not by decreasing the drug affinity for the kinase.


Asunto(s)
Proteínas Proto-Oncogénicas c-abl/química , Proteínas Proto-Oncogénicas c-abl/metabolismo , Regulación Alostérica , Humanos , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Conformación Proteica
8.
Science ; 355(6322): 247-248, 2017 01 20.
Artículo en Inglés | MEDLINE | ID: mdl-28104853
9.
Nat Chem Biol ; 12(2): 117-23, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26656091

RESUMEN

Cyclophilin A (CypA) is overexpressed in a number of human cancer types, but the mechanisms by which the protein promotes oncogenic properties of cells are not understood. Here we demonstrate that CypA binds the CrkII adaptor protein and prevents it from switching to the inhibited state. CrkII influences cell motility and invasion by mediating signaling through its SH2 and SH3 domains. CrkII Tyr221 phosphorylation by the Abl or EGFR kinases induces an inhibited state of CrkII by means of an intramolecular SH2-pTyr221 interaction, causing signaling interruption. We show that the CrkII phosphorylation site constitutes a binding site for CypA. Recruitment of CypA sterically restricts the accessibility of Tyr221 to kinases, thereby suppressing CrkII phosphorylation and promoting the active state. Structural, biophysical and in vivo data show that CypA augments CrkII-mediated signaling. A strong stimulation of cell migration is observed in cancer cells wherein both CypA and CrkII are greatly upregulated.


Asunto(s)
Ciclofilina A/farmacología , Proteínas Oncogénicas v-abl/metabolismo , Proteínas Proto-Oncogénicas c-crk/metabolismo , Transducción de Señal/efectos de los fármacos , Secuencia de Aminoácidos , Western Blotting , Calorimetría , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Humanos , Datos de Secuencia Molecular
10.
Nat Chem Biol ; 8(6): 590-6, 2012 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-22581121

RESUMEN

CrkL is a key signaling protein that mediates the leukemogenic activity of Bcr-Abl. CrkL is thought to adopt a structure that is similar to that of its CrkII homolog. The two proteins share high sequence identity and indistinguishable ligand binding preferences, yet they have distinct physiological roles. Here we show that the structures of CrkL and phosphorylated CrkL are markedly different than the corresponding structures of CrkII. As a result, the binding activities of the Src homology 2 and Src homology 3 domains in the two proteins are regulated in a distinct manner and to a different extent. The different structural architecture of CrkL and CrkII may account for their distinct functional roles. The data show that CrkL forms a constitutive complex with Abl, thus explaining the strong preference of Bcr-Abl for CrkL. The results also highlight how the structural organization of the modular domains in adaptor proteins can control signaling outcome.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/química , Proteínas de Fusión bcr-abl/metabolismo , Proteínas Nucleares/química , Proteínas Proto-Oncogénicas c-crk/química , Dominios Homologos src , Proteínas Adaptadoras Transductoras de Señales/genética , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Sitios de Unión , Proteínas de Fusión bcr-abl/genética , Humanos , Modelos Moleculares , Resonancia Magnética Nuclear Biomolecular , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Fosforilación , Proteínas Proto-Oncogénicas c-crk/genética , Proteínas Proto-Oncogénicas c-crk/metabolismo , Transducción de Señal
11.
Nat Chem Biol ; 7(1): 51-7, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21131971

RESUMEN

Proline switches, controlled by cis-trans isomerization, have emerged as a particularly effective regulatory mechanism in a wide range of biological processes. Here we report the structures of both the cis and trans conformers of a proline switch in the Crk signaling protein. Proline isomerization toggles Crk between two conformations: an autoinhibitory conformation, stabilized by the intramolecular association of two tandem SH3 domains in the cis form, and an uninhibited, activated conformation promoted by the trans form. In addition to acting as a structural switch, the heterogeneous proline recruits cyclophilin A, which accelerates the interconversion rate between the isomers, thereby regulating the kinetics of Crk activation. The data provide atomic insight into the mechanisms that underpin the functionality of this binary switch and elucidate its remarkable efficiency. The results also reveal new SH3 binding surfaces, highlighting the binding versatility and expanding the noncanonical ligand repertoire of this important signaling domain.


Asunto(s)
Prolina/química , Proteínas Proto-Oncogénicas c-crk/química , Transducción de Señal/efectos de los fármacos , Ciclofilina A/química , Ciclofilina A/metabolismo , Isomerismo , Ligandos , Prolina/farmacología , Unión Proteica/efectos de los fármacos , Conformación Proteica/efectos de los fármacos , Proteínas Proto-Oncogénicas c-crk/genética , Proteínas Proto-Oncogénicas c-crk/metabolismo , Transducción de Señal/fisiología , Dominios Homologos src/efectos de los fármacos
12.
Mol Cell ; 25(3): 413-26, 2007 Feb 09.
Artículo en Inglés | MEDLINE | ID: mdl-17289588

RESUMEN

Autoinhibition is being widely used in nature to repress otherwise constitutive protein activities and is typically regulated by extrinsic factors. Here we show that autoinhibition can be controlled by an intrinsic intramolecular switch afforded by prolyl cis-trans isomerization. We find that a proline on the linker tethering the two SH3 domains of the Crk adaptor protein interconverts between the cis and trans conformation. In the cis conformation, the two SH3 domains interact intramolecularly, thereby forming the basis of an autoinhibitory mechanism. Conversely, in the trans conformation Crk exists in an extended, uninhibited conformation that is marginally populated but serves to activate the protein upon ligand binding. Interconversion between the cis and trans, and, hence, of the autoinhibited and activated conformations, is accelerated by the action of peptidyl-prolyl isomerases. Proline isomerization appears to make an ideal switch that can regulate the kinetics of activation, thereby modulating the dynamics of signal response.


Asunto(s)
Prolina/química , Proteínas Proto-Oncogénicas c-crk/química , Isomerasas de Aminoácido/fisiología , Animales , Pollos , Isomerismo , Cinética , Ligandos , Modelos Biológicos , Resonancia Magnética Nuclear Biomolecular , Conformación Proteica , Estructura Terciaria de Proteína , Proteínas Proto-Oncogénicas c-crk/antagonistas & inhibidores , Termodinámica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...